What is Movair?
Formerly recognized as International Biophysics Corporation, Movair leverages over three decades of industry expertise to bridge the gap between clinical innovation and patient-centric care. The company is best known for its flagship AffloVest technology and the LUISA portable home ventilator, both of which are engineered to facilitate continuous, effortless breathing. By integrating advanced engineering with practical clinical applications, Movair has established a formidable market position, effectively transforming the standard of care for individuals requiring long-term respiratory support. Their portfolio reflects a deep commitment to enhancing patient quality of life through reliable, high-performance medical hardware.
How much funding has Movair raised?
Movair has raised a total of $988K across 2 funding rounds:
Debt
$350K
Debt
$638K
Debt (2020): $350K with participation from PPP
Debt (2021): $638K led by PPP
Key Investors in Movair
PPP
Public-Private Partnership
What's next for Movair?
With this major enterprise-level funding, Movair is well-positioned to accelerate its research and development pipeline and expand its footprint in the home-care respiratory market. The strategic allocation of these funds will likely focus on optimizing supply chain efficiencies and scaling the distribution of its core product lines. As the company continues to refine its treatment strategies, the focus remains on maintaining its competitive edge in the medical technology sector, ensuring that clinicians and patients alike have access to the most advanced respiratory support systems available. Future growth will likely be driven by further technological iterations and the expansion of its clinical support network.
See full Movair company page
